Comparative evaluation of therapeutic DNA vaccines against Trypanosoma cruzi in mice

FEMS Immunology and Medical Microbiology

Volumn 50, Issue 3, 2007, Pages 333-341

  Sanchez Burgos, Gilma ^a   Mezquita Vega, R Gabino ^a   Escobedo Ortegon, Javier ^a   Ramirez Sierra, Maria Jesus ^a   Arjona Torres, Arletty ^a   Ouaissi, Ali ^b   Rodrigues, Mauricio M ^c   Dumonteil, Eric ^a  

^a UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chagas disease; Immunotherapy; Protozoa; Therapeutic vaccine

Indexed keywords

DNA VACCINE; PARASITE ANTIGEN; PLASMID DNA; TRYPANOSOMA CRUZI VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHAGAS DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; MORTALITY; MOUSE; MYOCARDITIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITEMIA; PLASMID; PRIORITY JOURNAL; PROTOZOAL INFECTION; SURVIVAL; TRYPANOSOMA CRUZI;

EID: 34447257649     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2007.00251.x     Document Type: Article

References (51)

1. Abuin G, Freitas-Junior LH, Colli W, Alves MJ Schenkman S (1999) Expression of trans-sialidase and 85-kDa glycoprotein genes in Trypanosoma cruzi is differentially regulated at the post-transcriptional level by labile protein factors. J Biol Chem 274: 13041 13047.
2. Aguilar-Be I, da Silva Zardo R, Paraguai de Souza E, Borja-Cabrera GP, Rosado-Vallado M, Mut-Martin M, Garcia-Miss MR, Palatnik de Sousa CB Dumonteil E (2005) Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect Immun 73: 812 819.
3. Autran B, Carcelain G, Combadiere B Debre P (2004) Therapeutic vaccines for chronic infections. Science 305: 205 208.
4. Bahloul C, Ahmed SB, B'Chir BI, Kharmachi H, Hayouni el A Dellagi K (2003) Post-exposure therapy in mice against experimental rabies: a single injection of DNA vaccine is as effective as five injections of cell culture-derived vaccine. Vaccine 22: 177 184.
5. Bhatia V Garg N (2005) Current status and future prospects for a vaccine against American trypanosomiasis. Expert Rev Vaccines 4: 867 880.
6. Boscardin SB, Kinoshita SS, Fujimura AE Rodrigues MM (2003) Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infection. Infect Immun 71: 2744 2757.
7. Boyer JD, Ugen KE, Chattergoon M et al 1997) DNA vaccination as anti-human immunodeficiency virus immunotherapy in infected chimpanzees. J Infect Dis 176: 1501 1509.
8. Buckner F, Yokoyama K, Lockman J, Aikenhead K, Ohkanda J, Sadilek M, Sebti S, Van Voorhis W, Hamilton A Gelb MH (2003) A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc Natl Acad Sci USA 100: 15149 15153.
9. Castro JA, de Mecca MM Bartel LC (2006) Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum Exp Toxicol 25: 471 479.
10. Colorado IA, Acquatella H, Catalioti F, Fernandez MT Layrisse Z (2000) HLA class II DRB1, DQB1, DPB1 polymorphism and cardiomyopathy due to Trypanosoma cruzi chronic infection. Hum Immunol 61: 320 325.
11. Costa F, Franchin G, Pereira-Chioccola VL, Ribeirao M, Schenkman S Rodrigues MM (1998) Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice. Vaccine 16: 768 774.
12. Cruz-Robles D, Reyes PA, Monteon-Padilla VM, Ortiz-Muniz AR Vargas-Alarcon G (2004) MHC class I and class II genes in Mexican patients with Chagas disease. Hum Immunol 65: 60 65.
13. Dumonteil E, Escobedo-Ortegon J, Reyes-Rodriguez N, Ramirez-Sierra MJ Arjona-Torres A (2004) Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice. Infect Immun 72: 46 53.
14. El-Sayed NM, Myler PJ, Bartholomeu DC et al 2005) The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 309: 409 415.
15. Fernandez-Gomez R, Esteban S, Gomez-Corvera R, Zoulika K Ouaissi A (1998) Trypanosoma cruzi: Tc52 released protein-induced increased expression of nitric oxide synthase and nitric oxide production by macrophages. J Immunol 160: 3471 3479.
16. Fouts DL, Ruef BJ, Ridley PT, Wrightsman RA, Peterson DS Manning JE (1991) Nucleotide sequence and transcription of a trypomastigote surface antigen gene of Trypanosoma cruzi. Mol Biochem Parasitol 46: 189 200.
17. Fujimura AE, Kinoshita SS, Pereira-Chioccola VL Rodrigues MM (2001) DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene. Infect Immun 69: 5477 5486.
18. Garg N Tarleton RL (2002) Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect Immun 70: 5547 5555.
19. Garzon E, Borges MC, Cordeiro-da-Silva A, Nacife V, Meirelles Mde N, Guilvard E, Bosseno MF, Guevara AG, Breniere SF Ouaissi A (2003) Trypanosoma cruzi carrying a targeted deletion of a Tc52 protein-encoding allele elicits attenuated Chagas' disease in mice. Immunol Lett 89: 67 80.
20. Girones N Fresno M (2003) Etiology of Chagas disease myocarditis: autoimmunity, parasite persistence, or both? Trends Parasitol 19: 19 22.
21. Hoft DF Eickhoff CS (2002) Type 1 immunity provides optimal protection against both mucosal and systemic Trypanosoma cruzi challenges. Infect Immun 70: 6715 6725.
22. Kierszenbaum F (1999) Chagas' disease and the autoimmunity hypothesis. Clin Microbiol Rev 12: 210 223.
23. Kumkhaek C, Phra-Ek K, Renia L et al 2005) Are extensive T cell epitope polymorphisms in the Plasmodium falciparum circumsporozoite antigen, a leading sporozoite vaccine candidate, selected by immune pressure? J Immunol 175: 3935 3939.
24. Lai WC, Pakes SP, Ren K, Lu Y-S Bennett M (1996) Therapeutic effect of DNA immunization of genetically susceptible mice infected with virulent Mycoplasma pulmonis. J Immunol 158: 2513 2516.
25. Laucella SA, Postan M, Martin D, Hubby Fralish B, Albareda MC, Alvarez MG, Lococo B, Barbieri G, Viotti RJ Tarleton RL (2004) Frequency of interferon-gamma-producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J Infect Dis 189: 909 918.
26. Lodmell DL Ewalt LC (2001) Post-exposure DNA vaccination protects mice against rabies virus. Vaccine 19: 2468 2473.
27. Low HP, Santos MAM, Wizel B Tarleton RL (1998) Amastigote surface proteins of Trypanosoma cruzi are targets for CD8+CTL. J Immunol 160: 1817 1823.
28. Lowrie DB, Tascon RE, Bonato VLD, Lima VMF, Faccioli LH, Stravropoulos E, Colston MJ, Hewinson RG, Moelling K Silva CL (1999) Therapy of tuberculosis in mice by DNA vaccination. Nature 400: 269 271.
29. Martin DL, Weatherly DB, Laucella SA et al 2006) CD8+T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog 2: e77.
30. Miller MJ, Wrightsman RA Manning JE (1996) Trypanosoma cruzi: protective immunity in mice immunized with paraflagellar rod proteins is associated with a T-helper type 1 response. Exp Parasitol 84: 156 167.
31. Monteon-Padilla V, Hernandez-Becerril N, Ballinas-Verdugo MA, Aranda-Fraustro A Reyes PA (2001) Persistence of Trypanosoma cruzi in chronic chagasic cardiopathy patients. Arch Med Res 32: 39 43.
32. Ouaissi A, Aguirre T, Plumas Marty B et al 1992) Cloning and sequencing of a 24-kDa Trypanosoma cruzi specific antigen released in association with membrane vesicles and defined by a monoclonal antibody. Biol Cell 75: 11 17.
33. Ouaissi MA, Dubremetz JF, Schoneck R et al 1995) Trypanosoma cruzi: a 52-kDa protein sharing sequence homology with glutathione S-transferase is localized in parasite organelles morphologically resembling reservosomes. Exp Parasitol 81: 453 461.
34. Ouaissi A, Guilvard E, Delneste Y, Caron G, Magistrelli G, Herbault N, Thieblemont N Jeannin P (2002) The Trypanosoma cruzi Tc52-released protein induces human dendritic cell maturation, signals via Toll-like receptor 2, and confers protection against lethal infection. J Immunol 168: 6366 6374.
35. Paiva CN, Castelo-Branco MT, Lannes-Vieira J Gattass CR (1999) Trypanosoma cruzi: protective response of vaccinated mice is mediated by CD8+cells, prevents signs of polyclonal T lymphocyte activation, and allows restoration of a resting immune state after challenge. Exp Parasitol 91: 7 19.
36. Roberts LJ, Foote SJ Handman E (2000) A new standard for the assessment of disease progression in murine cutaneous leishmaniasis. Parasite Immunol 22: 231 237.
37. Rodrigues MM, Ribeirao M, Pereira-Chioccola V, Renia L Costa F (1999) Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene. Infect Immun 67: 3855 3863.
38. Rosado-Vallado M, Mut-Martin M, Garcia-Miss MR Dumonteil E (2005) Aluminium phosphate potentiates DNA vaccines against Leishmania mexicana. Vaccine 23: 5372 5379.
39. Santori FR, Paranhos Bacalla GS, Franco DASJ, Yamauchi LM, Araya JE Yoshida N (1996) A recombinant protein based on the Trypanosoma cruzi metacyclic trypomastigote 82-kilodalton antigen that induces an effective immune response to acute infection. Infect Immun 64: 1093 1099.
40. Silva JS, Vespa GN, Cardoso MA, Aliberti JC Cunha FQ (1995) Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages. Infect Immun 63: 4862 4867.
41. Steverding D Tyler KM (2005) Novel antitrypanosomal agents. Expert Opin Investig Drugs 14: 939 955.
42. Taibi A, Plumas-Marty B, Guevara-Espinoza A et al 1993) Trypanosoma cruzi: immunity-induced in mice and rats by trypomastigote excretory-secretory antigens and identification of a peptide sequence containing a T cell epitope with protective activity. J Immunol 151: 2676 2689.
43. Tarleton RL (2001) Parasite persistence in the aetiology of Chagas disease. Int J Parasitol 31: 550 554.
44. Ulmer JB, DeWitt CM, Chastain M, Friedman A, Donnelly JJ, McClements WL, Caulfield MJ, Bohannon KE, Volkin DB Evans RK (1999) Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine 18: 18 28.
45. Urbina JA Docampo R (2003) Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol 19: 495 501.
46. Urwin R, Russell JE, Thompson EA, Holmes EC, Feavers IM Maiden MC (2004) Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun 72: 5955 5962.
47. WHO (2002) Control of Chagas disease. World Health Organ Tech Rep Ser 905: 1 109.
48. Wizel B, Garg N Tarleton RL (1998) Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection. Infect Immun 66: 5073 5081.
49. Wrightsman RA, Dawson BD, Fouts DL Manning JE (1994) Identification of immunodominant epitopes in Trypanosoma cruzi trypomastigote surface antigen-1 protein that mask protective epitopes. J Immunol 153: 3148 3154.
50. Zapata-Estrella H, Hummel-Newell C, Sanchez-Burgos G, Escobedo-Ortegon J, Ramirez-Sierra MJ, Arjona-Torres A Dumonteil E (2006) Control of Trypanosoma cruzi infection and changes in T cell populations induced by a therapeutic DNA vaccine in mice. Immunol Lett 103: 186 191.
51. Zhang L Tarleton RL (1999) Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. J Infect Dis 180: 480 486.